We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$324M
AUM Growth
-$34.7M
Cap. Flow
-$47.6M
Cap. Flow %
-14.67%
Top 10 Hldgs %
60.32%
Holding
44
New
11
Increased
8
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10M
2
AHCO icon
AdaptHealth
AHCO
+$6.4M
3
TPB icon
Turning Point Brands
TPB
+$6.03M
4
PLXS icon
Plexus
PLXS
+$5.79M
5
ATRC icon
AtriCure
ATRC
+$5.3M

Top Sells

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$20.7M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$11M
3
UNH icon
UnitedHealth
UNH
+$10.3M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$7.6M
5
ABT icon
Abbott
ABT
+$6.86M

Sector Composition

Rank Sector Weight
1 Healthcare 89.76%
2 Technology 6.74%
3 Consumer Staples 1.76%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
1
Pacira BioSciences
PCRX
$1.02B
$39.4M 12.14%
655,000
-45,000
-6% -$2.61M
MDT icon
2
Medtronic
MDT
$107B
$26M 8.01%
250,000
+100,000
+67% +$10M
HOLX
3
DELISTED
Hologic
HOLX
$19.9M 6.15%
300,000
-25,000
-8% -$1.58M
PRGO icon
4
Perrigo
PRGO
$1.4B
$19.7M 6.08%
430,000
-45,000
-9% -$2.36M
RIGL icon
5
Rigel Pharmaceuticals
RIGL
$680M
$18M 5.55%
750,000
+65,000
+9% +$1.6M
UTHR icon
6
United Therapeutics
UTHR
$26.3B
$16.2M 4.98%
160,000
-15,000
-9% -$1.65M
MDRX
7
DELISTED
Veradigm Inc. Common Stock
MDRX
$15.5M 4.77%
1,900,000
+300,000
+19% +$2.45M
LH icon
8
Labcorp
LH
$24.3B
$15.1M 4.64%
93,120
+29,100
+45% +$4.61M
ATRC icon
9
AtriCure
ATRC
$1.77B
$14M 4.3%
350,000
+125,000
+56% +$5.3M
LNTH icon
10
Lantheus
LNTH
$6.82B
$12M 3.71%
950,000
– –
NUAN
11
DELISTED
Nuance Communications, Inc.
NUAN
$11.6M 3.58%
350,000
-225,000
-39% -$6.53M
DGX icon
12
Quest Diagnostics
DGX
$25.1B
$11.4M 3.53%
100,000
-175,000
-64% -$20.7M
ICUI icon
13
ICU Medical
ICUI
$3.93B
$11.1M 3.44%
61,000
-17,000
-22% -$3.2M
PLXS icon
14
Plexus
PLXS
$6.81B
$10.2M 3.16%
145,000
+79,000
+120% +$5.79M
PHR icon
15
Phreesia
PHR
$632M
$9.64M 2.97%
300,000
-100,000
-25% -$2.98M
RDNT icon
16
RadNet
RDNT
$4.84B
$9.59M 2.96%
625,000
-75,000
-11% -$1.18M
BIO icon
17
Bio-Rad Laboratories Class A
BIO
$8.42B
$7.73M 2.38%
15,000
-15,000
-50% -$7.6M
OPTN
18
DELISTED
OptiNose
OPTN
$7.21M 2.22%
123,333
+21,666
+21% +$1.6M
STRM
19
DELISTED
Streamline Health Solutions
STRM
$6.72M 2.07%
287,059
– –
AHCO icon
20
AdaptHealth
AHCO
$1.46B
$6.65M 2.05%
+305,000
New +$6.4M
SIBN icon
21
SI-BONE Inc
SIBN
$737M
$5.81M 1.79%
245,000
+139,800
+133% +$2.78M
TPB icon
22
Turning Point Brands
TPB
$1.47B
$5.72M 1.76%
+205,000
New +$6.03M
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.08M 1.56%
900,000
-100,000
-10% -$477K
EW icon
24
Edwards Lifesciences
EW
$47.6B
$3.99M 1.23%
+50,000
New +$3.9M
MSON
25
DELISTED
Misonix Inc
MSON
$3.52M 1.08%
300,000
-22,041
-7% -$286K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2020 Portfolio in Review

As of Q3 2020, Tamarack Advisers held 44 positions worth $324M, down 9.7% from $359M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Tamarack Advisers withdrew a net $47.6M in Q3 2020, closing 10 positions and reducing 13 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Tamarack Advisers opened a new position in AdaptHealth worth $6.65M.

  • Tamarack Advisers's largest Q3 2020 buy was AdaptHealth: 305,000 shares worth $6.65M.
  • Tamarack Advisers added most to Medtronic in Q3 2020, an estimated $10M increase.
  • Tamarack Advisers's biggest Q3 2020 reduction was Quest Diagnostics, cutting an estimated $20.7M.
  • Tamarack Advisers fully exited GW Pharmaceuticals Plc American Depositary Shares in Q3 2020, selling an estimated $11M.
  • Tamarack Advisers's ten largest holdings make up 60% of its $324M portfolio in Q3 2020.
  • Tamarack Advisers opened 11 new positions and closed 10 in Q3 2020.
  • Tamarack Advisers's portfolio value fell 9.7% quarter-over-quarter to $324M.

Based on Tamarack Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.